ArticleScientific reports2026
Association of RAS mutational status with clinical outcomes in metastatic colorectal cancer treated with trifluridine/tipiracil or regorafenib.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies demonstrated codon-specific KRAS mutation as a potential biomarker of resistance in metastatic colorectal cancer (mCRC). Our study aimed to evaluate the association of RAS status on survival in patients with mCRC treated with trifluridine/tipiracil (FTD/TPI) or regorafenib. mCRC Patients treated with FTD/TPI combination (FTD/TPIcombo), FTD/TPI monotherapy (FTD/TPImono) or regorafenib were retrospectively enrolled into our study. All patients were classified according to chemotherapy regimen and RAS status. Progression-free survival (PFS) and overall survival (OS) was estimated for comparison. Kaplan–Meier curves were plotted for survival. A total of 263 patients were enrolled into our study, accounting for 79 FTD/TPIcombo, 86 FTD/TPImono and 98 regorafenib. The median PFS and OS were 4.9 m, 3.0 m versus 2.5 m and 15.1 m, 11.3 m versus 7.3 m in FTD/TPIcombo, FTD/TPImono and regorafenib, respectively. The overall response rate were 23%, 7% versus 5% in FTD/TPIcombo, FTD/TPImono and regorafenib, respectively. Patients were stratified according to RAS status, accounting for 129 RASwild, 85 KRASG12mut and 51 RASOTHERmut. For patients with RASwild, the median OS was 16.2 m, 14.7 m and 6.5 m for FTD/TPIcombo, FTD/TPImono and regorafenib, respectively. For patients with KRASG12mut, the median OS was 9.5 m, 5.6 m and 8.4 months for FTD/TPIcombo, FTD/TPImono and regorafenib group, respectively. For patients with RASOTHERmut, the median OS was 13.4 m, 9.9 m and 5.0 months for FTD/TPIcombo, FTD/TPImono and regorafenib group, respectively. In conclusion, FTD/TPIcombo had superior survival across all RAS mutational status. Notably, regorafenib was associated with longer OS than FTD/TPI monotherapy in the KRASG12mut subgroup, whereas FTD/TPI monotherapy yielded longer OS than regorafenib in patients with RASwild and RASOTHERmut status. These results suggest a potential role for RAS status in treatment selection and strongly support the need for prospective, randomized trials to confirm these observations before they can be translated into clinical practice guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.